trending Market Intelligence /marketintelligence/en/news-insights/trending/RMtWRTgrOEkEpEG9MizL4Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Premier Biomedical to form JV to manufacture, sell anti-addiction patches

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Premier Biomedical to form JV to manufacture, sell anti-addiction patches

Premier Biomedical Inc. agreed to form a joint venture with New Earth Development Corp., RushNet Inc., and XYZ Hemp Inc. to manufacture and sell anti-addiction patches.

The product will be based on topical pain relieving patch technology marketed by Premier Biomedical.

The anti-addiction patch contains hemp oil extracts and a patented combination of U.S. Food and Drug Administration-approved drugs naltrexone and cyclobenzaprine.

The patch is expected to eliminate a desire for opioid abuse. Each patch is designed to provide continuous treatment for seven to 10 days.

The joint venture is targeting global sales due to the opioid epidemic in the U.S. and internationally, Premier Biomedical said in a news release.